Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

Also called NCT06055452

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06055452
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06055452. Randomized; quadruple masking; primary purpose prevention. Start 2024-01-19 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension
Condition
Pre-Heart Failure
Condition
Hypertension
Intervention (Drug)
Empagliflozin 10 MG
Intervention (Drug)
Placebo
Lead sponsor
China National Center for Cardiovascular Diseases (class: other government)

Record details

Record id
cardio:ct-nct06055452
Content hash
19e62c70355c3b9c0945a344bd906019f581e74a440a845370d84c7446fdd7c7